MORI-BUILDING
18.2.2021 06:02:05 CET | Business Wire | Press release
Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that it will partner with Aman, the operator of diverse world-class luxury hotels and resorts, in the Toranomon-Azabudai Urban Redevelopment Project, a massive urban renewal undertaking that will revitalize a large area of central Tokyo when completed in 2023. The two main outcomes of the partnership will be the branded residence Aman Residences, Tokyo and luxury hotel Janu Tokyo , Aman’s sister brand, marking the debut of the Janu brand in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217006076/en/
Shingo Tsuji, President and CEO of Mori Building, said: “Tokyo must add to its magnetic power if it is to succeed in its competition with the world’s greatest cities. Mori Building is joining hands with Aman, which operates diverse world-class resorts, to provide a world-leading residential environment and hotel unlike anything ever seen in Tokyo, where people will achieve harmony with nature as well as connect with and inspire others through creativity. By realizing this new form of ‘urban wellness,’ Mori Building will enhance Tokyo's magnetic power.”
Vladislav Doronin, Chairman and CEO of Aman and Janu, said: “Launching our first urban Aman Residences in Japan is a milestone moment in the history of Aman and speaks to our brand’s close relationship and symbiosis with this country and its incredibly special culture. Working with leading developers Mori Building, and being part of the Toranomon-Azabudai project, will enable us to bring to life Aman’s fifth development within Japan, this time offering a permanent sanctuary for owners as well as exclusive access to the Aman lifestyle. Furthermore, it will provide the setting for Janu Tokyo. In this hub of culture and art, we want to connect guests to the heart of this vibrant community and offer a chance for creative expression.”
Aman Residences, Tokyo — incomparable urban residential experiences
Aman Residences, Tokyo will be located on floors 54–64 of the 330-meter A District Tower, will offer 91 hotel-branded residences with exclusive services, including a residents-only Aman Spa (some 1,400 m²). Aman’s signature hospitality—both warm and unassuming—will enable residents to enjoy extraordinarily peaceful lifestyles while overlooking the vibrant Tokyo metropolis. The Tower’s sophisticated architectural design is the masterful work of Pelli Clarke Pelli Architects (USA) and interior design has been crafted by Yabu Pushelberg (Canada).
Janu Tokyo — Aman’s sister brand debuts in Japan
Aman’s luxury hotel brand Janu will make its Japan debut with Janu Tokyo on floors 1–13 in the B-2 District Tower. The hotel is designed by Denniston (Malaysia) under the leadership of Jean-Michel Gathy. In addition to approx. 120 luxury rooms, all offering excellent views of a central square filled with lush greenery, Janu Tokyo will boast Japan’s largest spa (some 3,500 m²) with spa treatment and a fitness center, six restaurants, and a cafe and bars for leisure and business gatherings. Janu Tokyo will welcome guests from around the world.
About Aman
Aman was founded in 1988 with the vision of building a collection of intimate retreats with the unassuming, warm hospitality of a gracious private home. The first, Amanpuri (place of peace) in Phuket, Thailand, introduced the concept and, since then, Aman has grown to encompass 33 exquisitely serene hotels and resorts in 20 destinations across the world, with a further seven under construction. The next Aman to open will be Aman New York. In 2020, a new hotel brand, Janu - meaning ‘soul’ in Sanskrit was unveiled. Janu offers a unique take on hospitality where genuine human interaction, playful expression and social wellness are at the core of the experience. Janu aims to bring balance to the head and heart and rekindle the soul. Janu launches with three forthcoming hotels which are already under construction: Montenegro (2022), Al Ula in Saudi Arabia (2022) and Tokyo (2023), as well as a robust pipeline of future hotels.
About Mori Building
Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en
Related Links
Press release “Mori Building Unveils Massive Urban Regeneration Project In Central Tokyo” published on August 22, 2019:
https://www.mori.co.jp/en/img/article/190822.pdf
Toranomon-Azabudai Project Fact Book:
https://www.mori.co.jp/en/projects/toranomon_azabudai/img/fact_book.pdf
Toranomon-Azabudai Project Image Movie:
https://www.youtube.com/watch?v=5akVE7tWOto&feature=emb_logo
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217006076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
